Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) is one of 846 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Autolus Therapeutics to similar businesses based on the strength of its profitability, valuation, earnings, institutional ownership, analyst recommendations, dividends and risk.
Analyst Ratings
This is a summary of current recommendations and price targets for Autolus Therapeutics and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autolus Therapeutics | 1 | 1 | 3 | 2 | 2.86 |
| Autolus Therapeutics Competitors | 9905 | 15274 | 45603 | 1595 | 2.54 |
Autolus Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 657.58%. As a group, “Biotechnology” companies have a potential upside of 99.41%. Given Autolus Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Autolus Therapeutics is more favorable than its rivals.
Valuation and Earnings
This table compares Autolus Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Autolus Therapeutics | $117.39 million | -$287.53 million | -1.25 |
| Autolus Therapeutics Competitors | $729.47 million | $11.46 million | -14.85 |
Autolus Therapeutics’ rivals have higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Autolus Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autolus Therapeutics | -238.66% | -178.66% | -49.34% |
| Autolus Therapeutics Competitors | -12,285.98% | -196.04% | -30.61% |
Institutional and Insider Ownership
72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Autolus Therapeutics has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, Autolus Therapeutics’ rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.
Summary
Autolus Therapeutics beats its rivals on 9 of the 13 factors compared.
Autolus Therapeutics Company Profile
Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety. Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
